Knowledge Check

Exam-style MCQs aligned with these notes. Available to Hyperexcision Scholar members.

Log in to access
Last updated: June 24, 2026Bookmark

Endometriosis is the presence of endometrial glands and stroma outside the endometrial cavity. It presents with cyclical pelvic pain and severe dysmenorrhoea since it is oestrogen and progesterone-sensitive.

  • Risk factors
    • Family history
    • Anatomic defects
      • There is increased incidence with obstructive defects
    • Nulliparity
    • Early menarche
    • Late menopause
    • Short menstrual cycle (< 27 days)
    • Longer duration of menstrual flow
    • Menorrhagia (> 1 week)
    • Other environmental factors
      • TCDD/Dioxins (industrial pollutants)
      • Caffeine
      • Alcohol use
  • Protective factors
    • Regular exercise
    • High parity
    • Longer duration of lactation
  • Pathophysiology
    • Theories
      • Retrograde menstruation: dissemination of endometrial fragments into the peritoneal cavity due to uterine hyperperistalsis/dysperistalsis. This explains endometriosis in women with outflow obstruction.
      • Lymphatic/vascular spread: this is the theory behind its spread into abnormal locations, e.g., retro-orbital
      • Coelomic metaplasia (Meyer’s theroy): suggests that the parietal peritoneum is pluripotent and can transform into endometrial tissue. This explains why some men can get endometriosis.
      • Induction theory: exposure to estrogen induces tranformation of certain tissues into endometrial-like tissue. The ovarian surface epithelium can transform into endometrial like-tissue.
      • Immune dysfunction: this theory isvery complex…
    • Sites of ectopic implantation
      • Dependent areas of the pelvis
        • Anterior and posterior cul-de-sac
        • Uterosacral ligaments
        • Rectovaginal septum
      • Ovary
        • Haemorrhagic cysts known as endometriomas or chocolate cysts.
        • Endometriomas are less likely to produce tosion than other cysts due since they are surrounded by adhesions
      • Bladder
      • Ureters
      • Anterior abdominal wall
      • Diaphragm
    • Regardless of location of endometrial tissue it responds to the normal hormonal cycle resulting in:
      • Production of inflammatory and pain mediators
      • Infertility
      • Nerve dysfunction
    • There is increased prostaglandin and oestrogen formation leading to chronic inflammation (IL 1, IL6, IL 8, TNF alpha all play a role) = PAIN
      • Premenstruation – the tissue is stimulated to grow by progesterone and oestrogen. They enlarge and undergo secretory changes and bleeding.
    • However, surrounding tissues prevent expansion and enlargement of the hemorrhagic fluid causing an increase in pressure = PAIN
    • Severe pain is seen in cases where there are deeply infiltrating lesions.
  • Signs and symptoms
    • Pain
      • Cyclical superimposed on chronic
    • Chronic pelvic pain
      • Localized
      • Radiating to the upper back or leg
    • Dysmenorrhoea
      • Pain precedes menses by 24-48 hours
      • Less responsive to NSAIDs and combined oral contraceptives
    • Dyspareunia
      • This is partly caused by implants in the uterosacral ligament
    • Dysuria
      • This is associated with cyclical frequency and urgency
    • Defecatory pain
    • Infertility or subfertility
      • This occurs when the implants disrupt tubo-ovarian structures or implant in the ovaries
    • Symptoms of intestinal obstruction
    • Symptoms of urethral obstruction
  • Physical exam
    • Blue or powder-burn red lesions which bleed easily can sometimes be seen on speculum exam
    • Uterosacral ligament nodularity and tenderness
    • Fixed, tender and retroverted uterus
    • Palpable (enlarged) cystic adnexal mass
    • Fixed, firm posterior cul-de-sac
  • Differentials
  • Investigations
    • Transvaginal ultrasound to identify endometriomas
      • The uterus is generally not enlarged
      • An endometrioma appears as a homogenous cystic lesion with ground-glass internal echos, which surround a normal-appearing ovarian stroma
      • Nodules
    • CT-scan or MRI
    • Diagnostic laparoscopy + biopsy for definitive diagnosis
      • Endometrial glands and stroma outside the endometrial cavity
      • Red lesions
      • White/clear implants
      • Black-brown “powder-burn” lesions
      • Endometriomas (brown-black cystic lesions of the ovary classically filled with chocolate-colored fluid)
    • Complete blood count
    • Urine hCG
    • Urinalysis + culture
    • Vaginal/Cervical culture
  • Treatment
    • NSAIDS (ibruprofen or naproxen) for primary dysmenorrhoea and pelvic pain prior to laparoscopic diagnosis or confirmed endometriosis with mild symptoms
    • Combined oral contraceptives (COCs) to reduce endometriorsis-related pain
    • Progestins for patients with contraindications to oestrogens
      • Depot medroxyprogesterone acetate (DMPA) can reduce bone mineral density
      • Norethindrone acetate is very effective with Leuprolide
      • Levonorgestrel-intrauterine system
      • Ulipristal acetate(Ella)
      • Mifepristone (off-label)
      • Norethisterone
    • Androgens (danazol or gestrinone)
      • These have a significant adverse effect profile
    • GnRH agonists (leuprolide, goserelin, or nafarelin)
      • These decrease pituitary GnRH production and downstream ovarian estrogen production.
      • An initial gonadotropin surge may worsen symptoms for 1-2 weeks before improvment.
      • Add-back therapy (low-dose estrogen and progestin supplementation) may be required to minimize hypoestrogenic and osteoporotic side effects
    • Aromatase inhibitors (anastrozole, or letrozole)
    • Surgery is the definitive treatment
      • Lesion ablation with adhesiolysis
      • Endometrioma resection
      • Presacral neurectomy
      • Cystectomy is preferred over cyst aspiration for endometriomas
      • Bilateral salpingo-oophorectomy for persistent symptoms despite medical treatment and previous surgery
      • Hysterectomy with bilateral salpingoophorectomy is the most definitive surgical treatment. It is considered in women who do not wish to preserve fertility
Reference Intervals
Biochemistry
ACTHP: <80 ng/L
ALTP: 5–35 U/L
AlbuminP: 35–50 g/L
AldosteroneP: 100–500 pmol/L
Alk. phosphataseP: 30–130 U/L
α-AmylaseP: 0–180 IU/dL
α-FetoproteinS: <10 kU/L
Angiotensin IIP: 5–35 pmol/L
ADHP: 0.9–4.6 pmol/L
ASTP: 5–35 U/L
BicarbonateP: 24–30 mmol/L
BilirubinP: 3–17 μmol/L
BNPP: <50 ng/L
CRPP: <10 mg/L
CalcitoninP: <0.1 mcg/L
Calcium (ionized)P: 1.0–1.25 mmol/L
Calcium (total)P: 2.12–2.60 mmol/L
ChlorideP: 95–105 mmol/L
CholesterolP: <5.0 mmol/L
VLDLP: 0.128–0.645 mmol/L
LDLP: <2.0 mmol/L
HDLP: 0.9–1.93 mmol/L
Cortisol AMP: 450–700 nmol/L
Cortisol MidnightP: 80–280 nmol/L
CK ♂P: 25–195 U/L
CK ♀P: 25–170 U/L
CreatinineP: 70–100 μmol/L
FerritinP: 12–200 mcg/L
FolateS: 2.1 mcg/L
FSHP: 2–8 U/L ♂; >25 menopause
GGT ♂P: 11–51 U/L
GGT ♀P: 7–33 U/L
Glucose (fasting)P: 3.5–5.5 mmol/L
Growth hormoneP: <20 mu/L
HbA1C (DCCT)B: 4–6%
HbA1C (IFCC)B: 20–42 mmol/mol
Iron ♂S: 14–31 μmol/L
Iron ♀S: 11–30 μmol/L
Lactate (venous)P: 0.6–2.4 mmol/L
Lactate (arterial)P: 0.6–1.8 mmol/L
LDHP: 70–250 U/L
LHP: 3–16 U/L
MagnesiumP: 0.75–1.05 mmol/L
OsmolalityP: 278–305 mosmol/kg
PTHP: 0.8–8.5 pmol/L
PotassiumP: 3.5–5.3 mmol/L
Prolactin ♂P: <450 U/L
Prolactin ♀P: <600 U/L
PSAP: 0–4 mcg/mL
Protein (total)P: 60–80 g/L
Red cell folateB: 0.36–1.44 μmol/L
Renin (erect)P: 2.8–4.5 pmol/mL/h
Renin (recumbent)P: 1.1–2.7 pmol/mL/h
SodiumP: 135–145 mmol/L
TBGP: 7–17 mg/L
TSHP: 0.5–4.2 mU/L
T4P: 70–140 nmol/L
Free T4P: 9–22 pmol/L
TIBCS: 54–75 μmol/L
TriglyceridesP: 0.50–2.3 mmol/L
T3P: 1.2–3.0 nmol/L
Troponin TP: <0.1 mcg/L
Urate ♂P: 210–480 μmol/L
Urate ♀P: 150–390 μmol/L
UreaP: 2.5–6.7 mmol/L
Vitamin B12S: 0.13–0.68 nmol/L
Vitamin DS: 50 nmol/L
Arterial Blood Gases
pH7.35–7.45
PaCO₂4.7–6.0 kPa
PaO₂>10.6 kPa
Base excess±2 mmol/L
Urine
Cortisol (free)<280 nmol/24h
Hydroxyindole acetic acid16–73 μmol/24h
Hydroxymethylmandelic acid16–48 μmol/24h
Metanephrines0.03–0.69 μmol/mmol cr.
Osmolality350–1000 mosmol/kg
17-Oxogenic steroids ♂28–30 μmol/24h
17-Oxogenic steroids ♀21–66 μmol/24h
17-Oxosteroids ♂17–76 μmol/24h
17-Oxosteroids ♀14–59 μmol/24h
Phosphate (inorganic)15–50 mmol/24h
Potassium14–120 mmol/24h
Protein<150 mg/24h
Protein/creatinine ratio<3 mg/mmol
Sodium100–250 mmol/24h
Haematology
WCC4.0–11.0 ×10⁹/L
RBC ♂4.5–6.5 ×10¹²/L
RBC ♀3.9–5.6 ×10¹²/L
Hb ♂130–180 g/L
Hb ♀115–160 g/L
PCV ♂0.4–0.54 L/L
PCV ♀0.37–0.47 L/L
MCV76–96 fL
MCH27–32 pg
MCHC300–360 g/L
RDW11.6–14.6%
Neutrophils2.0–7.5 ×10⁹/L (40–75%)
Lymphocytes1.0–4.5 ×10⁹/L (20–45%)
Eosinophils0.04–0.44 ×10⁹/L (1–6%)
Basophils0–0.10 ×10⁹/L (0–1%)
Monocytes0.2–0.8 ×10⁹/L (2–10%)
Platelets150–400 ×10⁹/L
Reticulocytes0.8–2.0% / 25–100 ×10⁹/L
Prothrombin time10–14 s
APTT35–45 s
Paediatric
Pulse Rate (bpm)
Neonate140–160
Infant <1yr120–140
1–5 years110–130
5–12 years80–120
>12 years70–100
Respiratory Rate (tachypnoea)
0–2 months≥60/min
2–12 months≥50/min
1–5 years≥40/min
>5 years≥30/min
Blood Pressure (mmHg)
Term65/45
1 year75/50
4 years85/60
8 years95/65
10 years100/70
Weight Formulas
3–12 months(a + 9)/2 kg
1–6 years2a + 8 kg
>6 years(7a − 5)/2 kg
Haemoglobin (g/dL)
Term newborn13–20
1 month11–18
2 months10–15
1–2 years10–13
>2 years11–14
MUAC (6 months–5 years)
Obese>17.5 cm
Normal13.5–17.4 cm
At risk12.5–13.4 cm
Moderate malnutrition11.5–12.4 cm
Severe malnutrition<11.5 cm
Developmental Milestones
Social smile1.5 months
Head control4 months
Sits unsupported7 months
Crawls10 months
Stands unsupported10–12 months
Walks12–13 months
Talks18 months
CSF WBC (/mm³)
Term newborn0–25
>2 weeks0–5
Calculator

Leave a Reply

A moment of your time
Step 1 of 2

You are the reason this exists. Got 60 seconds? Help us improve Hyperexcision for every medical student who uses it.

The Hyperexcision Team